Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nutra Pharma Corp. (NPHC)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Drug Manufacturers - Specialty & Generic
Address
1537 NW 65th Avenue 33313
Plantation, FL, US
Plantation, FL, US
CEO
Michael D. Flax
Website
nutrapharma.com
IPO
2001-12-06
CIK 1119643 ISIN US67060U2087
Description
Nutra Pharma Corp. (NPHC) operates as a biopharmaceutical firm specializing in obtaining, licensing, and bringing to market a variety of pharmaceutical products, cutting-edge technologies, and both homeopathic and ethical medications. The company primarily targets the U.S. market, focusing its efforts on managing conditions such as pain, neurological ailments, cancer, autoimmune diseases, and infectious diseases. Its current commercial offerings include: Nyloxin and Nyloxin Extra Strength: These products are distributed as an oral spray for alleviating lower back pain, migraines, neck and shoulder discomfort, cramps, and neuropathic pain, and as a topical gel to relieve joint pain, arthritis, and repetitive stress injuries. Pet Pain-Away: An over-the-counter (OTC) homeopathic, non-narcotic, and non-addictive solution for chronic pain in household pets. Luxury Feet: An OTC pain reliever and anti-inflammatory designed to ease foot pain or discomfort specifically caused by high heels and stilettos. Nyloxin Military Strength: A specialized formulation for pain relief aimed at the United States Military and Veteran's Administration. Equine Pain-Away: An OTC topical pain management product for horses. Beyond its existing portfolio, Nutra Pharma Corp. is also advancing several pipeline candidates: RPI-78M: In development to treat neurological conditions such as multiple sclerosis, adrenomyeloneuropathy, and amyotrophic lateral sclerosis, alongside autoimmune diseases like rheumatoid arthritis and myasthenia gravis. RPI-MN: Under investigation for viral diseases, including human immunodeficiency virus (HIV/AIDS) and herpes, as well as for general antiviral applications. RPI-78: Being developed for applications in pain and arthritis. RPI-70: Also in development for pain relief. Founded in 2000, the company is headquartered in Plantation, Florida.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
550.2K
Beta
-2.91
Float Shares
7.09B
Free Float %
99.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -66.67% | +0.00% | -80.00% | +0.00% | +0.00% | +0.00% | -98.39% | -98.82% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.00
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-219.94
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
4 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-12.1% Q1'26: -63.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-175.0% Q1'26: +50.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-419.4% Q1'26: -1,203.1% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-379.5% Q1'26: +0.0% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-59.3% ★ Q1'26: +4.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-7.17× Q1'26: -6.60× (vs Q1'25)
Valuation Multiples
From
To
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-1.01M
OE per share TTM
0.00
Owner's Yield
-125.62%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
67.4%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
3
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Rik. J. Deitsch | 3.04B | 57.00% | 3.04B | — | 3.04B | 10.00 | IN | USA | 2018-06-29 | ↗ |
| 2 | Lake Shore Advisors, LLC | 187.50M | 8.04% | 187.50M | — | 187.50M | 10.00 | CO | Ohio | 2018-06-06 | ↗ |
| 3 | Rik J. Deitsch | 55.30M | 62.30% | 55.30M | — | 55.30M | — | IN | United States | 2022-01-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
0
Sells
1
Shares acquired
—
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-11-15 | DEITSCH RIK J | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 43,298,859 | — | ↗ |
| 2017-10-30 | DEITSCH RIK J | Director / Officer / 10% Owner | A-Award | A | Nutra Pharma Series A Preferred | 3,000,000 | 0.00 | — | 3,000,000 | — | ↗ |
| 2016-12-19 | DEITSCH RIK J | Director / Officer / 10% Owner | P-Purchase | A | Nutra Pharma Corp Common Stock | 15,000,000 | 0.01 | 75.0K | 43,298,859 | — | ↗ |
| 2016-07-05 | DEITSCH RIK J | Director / Officer / 10% Owner | P-Purchase | A | Nutra Pharma Corp Common Stock | 15,000,000 | 0.01 | 100.5K | 28,298,859 | — | ↗ |
| 2016-06-28 | DEITSCH RIK J | Director / Officer / 10% Owner | A-Award | A | Nutra Pharma Corp Common Stock | 4,000,000 | 0.01 | 54.0K | 13,298,859 | — | ↗ |
| 2016-06-17 | ORAN DAN | Director | — | D | Common Stock | 0 | 0.00 | — | 1,006,229 | — | ↗ |
| 2015-06-13 | DEITSCH RIK J | Director / Officer / 10% Owner | A-Award | A | Nutra Pharma Corp Common Stock | 4,000,000 | 0.19 | 740.0K | 9,298,859 | — | ↗ |
| 2014-12-11 | DEITSCH RIK J | Director / Officer / 10% Owner | A-Award | A | Nutra Pharma Corp Common Stock | 506,900 | 0.24 | 121.7K | 5,298,859 | — | ↗ |
| 2014-04-10 | DEITSCH RIK J | Director / Officer / 10% Owner | P-Purchase | A | Nutra Pharma Corp Common Stock | 1,250,000 | 0.08 | 100.0K | 4,791,959 | — | ↗ |
| 2013-11-25 | Rumph Harold Henry | Director / Officer | A-Award | A | Nutra Pharma Corp | 7,400,000 | 0.01 | 103.6K | 35,000,000 | — | ↗ |
| 2013-11-25 | POTTRUCK GARRY | Director | A-Award | A | Nutra Pharma Corp | 6,890,000 | 0.01 | 96.5K | 17,815,000 | — | ↗ |
| 2013-11-25 | DEITSCH RIK J | Director / Officer / 10% Owner | A-Award | A | Nutra Pharma Corp | 11,760,000 | 0.01 | 164.6K | 141,678,334 | — | ↗ |
| 2013-10-18 | Lonky Stewart Alan | Director | D-Return | A | NPHC Common Stock | 70,000 | 0.01 | 560.00 | 20,220,000 | — | ↗ |
| 2013-09-09 | Rumph Harold Henry | Director / Officer | P-Purchase | A | Nutra Pharma Corp | 14,800,000 | 0.00 | 37.0K | 27,600,000 | — | ↗ |
| 2013-09-09 | DEITSCH RIK J | Director / Officer / 10% Owner | P-Purchase | A | Nutra Pharma Corp | 25,000,000 | 0.00 | 62.5K | 129,918,334 | — | ↗ |
| 2013-06-27 | DEITSCH RIK J | Director / Officer / 10% Owner | P-Purchase | A | Nutra Pharma Corp | 25,000,000 | 0.00 | 100.0K | 104,918,334 | — | ↗ |
| 2013-03-08 | Lonky Stewart Alan | Director | A-Award | A | NPHC Common Stock | 7,730,000 | 0.01 | 77.3K | 20,150,000 | — | ↗ |
| 2012-12-19 | DEITSCH RIK J | Director / Officer / 10% Owner | P-Purchase | A | Nutra Pharma Corp | 10,000,000 | 0.01 | 100.0K | 79,918,334 | — | ↗ |
| 2012-12-10 | DEITSCH RIK J | Director / Officer / 10% Owner | P-Purchase | A | Nutra Pharma Corp | 200,000 | 0.01 | 3.0K | 69,918,334 | — | ↗ |
| 2012-10-18 | Rumph Harold Henry | Director / Officer | A-Award | A | Nutra Pharma Corp | 5,000,000 | 0.02 | 110.0K | 12,800,000 | — | ↗ |
| 2012-10-18 | POTTRUCK GARRY | Director | A-Award | A | Nutra Pharma Corp | 5,500,000 | 0.02 | 121.0K | 10,925,000 | — | ↗ |
| 2012-10-18 | Lonky Stewart Alan | Director | A-Award | A | NPHC Common Stock | 5,000,000 | 0.00 | — | 12,420,000 | — | ↗ |
| 2012-10-18 | DEITSCH RIK J | Director / Officer / 10% Owner | A-Award | A | Nutra Pharma Corp | 7,500,000 | 0.02 | 165.0K | 69,718,334 | — | ↗ |
| 2012-08-30 | SARTORI BRUNO | — | S-Sale | D | Common Stock | 303,990 | 0.01 | 3.3K | 240,000 | — | ↗ |
| 2012-06-01 | SARTORI BRUNO | — | P-Purchase | A | Common Stock | 8,100 | 0.01 | 105.30 | 486,100 | — | ↗ |
| 2012-05-31 | SARTORI BRUNO | — | P-Purchase | A | Common Stock | 10,000 | 0.01 | 130.00 | 478,000 | — | ↗ |
| 2012-05-30 | SARTORI BRUNO | — | P-Purchase | A | Common Stock | 8,000 | 0.02 | 120.00 | 468,000 | — | ↗ |
| 2012-05-22 | SARTORI BRUNO | — | P-Purchase | A | Common Stock | 7,000 | 0.01 | 77.00 | 460,000 | — | ↗ |
| 2012-04-26 | SARTORI BRUNO | — | P-Purchase | A | Common Stock | 105,000 | 0.01 | 1.2K | 453,000 | — | ↗ |
| 2012-04-25 | SARTORI BRUNO | — | P-Purchase | A | Common Stock | 68,000 | 0.01 | 782.00 | 348,000 | — | ↗ |
| 2012-04-24 | SARTORI BRUNO | — | P-Purchase | A | Common Stock | 10,000 | 0.01 | 135.00 | 280,000 | — | ↗ |
| 2012-04-23 | SARTORI BRUNO | — | P-Purchase | A | Common Stock | 25,000 | 0.01 | 287.50 | 270,000 | — | ↗ |
| 2012-04-23 | DEITSCH RIK J | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 148,000 | 1,741.88 | 257.80M | 62,218,334 | — | ↗ |
| 2012-02-10 | SARTORI BRUNO | — | A-Award | A | Common Stock | 240,000 | 0.00 | — | 240,000 | — | ↗ |
| 2012-02-10 | Rumph Harold Henry | Director / Officer | A-Award | A | Nutra Pharma Corp | 4,000,000 | 0.02 | 66.0K | 7,800,000 | — | ↗ |
| 2012-02-10 | POTTRUCK GARRY | Director | A-Award | A | Nutra Pharma Corp | 2,875,000 | 0.02 | 47.4K | 5,425,000 | — | ↗ |
| 2012-02-10 | Lonky Stewart Alan | Director | A-Award | A | Common Stock | 4,400,000 | 77,000.00 | 338.80B | 7,420,000 | — | ↗ |
| 2012-02-10 | DEITSCH RIK J | Director / Officer / 10% Owner | A-Award | A | Common Stock | 6,800,000 | 0.02 | 119.0K | 62,070,334 | — | ↗ |
| 2011-01-20 | Lonky Stewart Alan | Director | P-Purchase | A | NPHC Common Stock | 10,000 | 0.13 | 1.3K | 3,020,000 | — | ↗ |
| 2010-12-31 | ISSERMAN DAVID MICHAEL | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2010-12-21 | Lonky Stewart Alan | Director | P-Purchase | A | NPHC Common Stock | 10,000 | 0.08 | 800.00 | 3,010,000 | — | ↗ |
| 2010-04-09 | Rumph Harold Henry | Director / Officer | S-Sale | D | Nutra Pharma Corp | 400,000 | 0.39 | 156.0K | 3,800,000 | — | ↗ |
| 2010-02-17 | Rumph Harold Henry | Director | P-Purchase | D | Nutra Pharma Corp | 50,000 | 0.46 | 23.0K | 4,200,000 | — | ↗ |
| 2010-02-12 | Rumph Harold Henry | Director | P-Purchase | D | Nutra Pharma Corp | 50,000 | 0.40 | 20.0K | 4,250,000 | — | ↗ |
| 2010-02-11 | ISSERMAN DAVID MICHAEL | Officer | — | D | Common Stock | 0 | 0.00 | — | 3,312,160 | — | ↗ |
| 2010-02-03 | Rumph Harold Henry | Director | P-Purchase | D | Nutrapharma Corp | 50,000 | 0.37 | 18.5K | 4,300,000 | — | ↗ |
| 2010-01-21 | Rumph Harold Henry | Director | P-Purchase | D | Nutrapharma Corp | 50,000 | 0.33 | 16.5K | 4,350,000 | — | ↗ |
| 2009-11-05 | Rumph Harold Henry | Director | — | D | Nutra Pharma Corp | 0 | 0.00 | — | 4,400,000 | — | ↗ |
| 2009-07-29 | POTTRUCK GARRY | Director | — | D | Common Stock | 0 | 0.00 | — | 2,500,000 | — | ↗ |
| 2009-06-18 | REID PAUL F | Director | A-Award | D | Common Stock | 7,000,000 | 0.03 | 186.9K | 0 | — | ↗ |
| 2008-04-28 | Rumph Harold Henry | Director | — | D | Nutra Pharma Corp | 0 | 0.00 | — | 4,400,000 | — | ↗ |
| 2008-04-14 | REID PAUL F | Director | — | D | Common Stock | 0 | 0.00 | — | 7,000,000 | — | ↗ |
| 2008-03-18 | Lonky Stewart Alan | Director | A-Award | A | Common Stock | 2,500,000 | 0.00 | — | 3,000,000 | — | ↗ |
| 2008-03-18 | CHERELSTEIN STANLEY JACK | Director | A-Award | A | Common Stock | 2,500,000 | 0.00 | — | 3,000,000 | — | ↗ |
| 2008-03-14 | DEITSCH RIK J | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 48,000,000 | 0.03 | 1.20M | 54,500,000 | — | ↗ |
| 2008-03-13 | DEITSCH RIK J | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 5,000,000 | 0.03 | 125.0K | 6,500,000 | — | ↗ |
| 2006-04-01 | DOHERTY MICHAEL | Director / Officer | A-Award | A | Option | 2,000 | 0.27 | 540.00 | 2,000,000 | — | ↗ |
| 2005-06-01 | DOHERTY MICHAEL | Director / Officer | A-Award | A | Option | 13,600,000 | 0.27 | 3.67M | 13,600,000 | — | ↗ |
| 2005-01-26 | Lonky Stewart Alan | Director | — | D | Common Stock | 0 | 0.00 | — | 50,000 | — | ↗ |
| 2005-01-26 | Khandaker Tanvir A | Director | — | D | Common stock | 0 | 0.00 | — | 500,000 | — | ↗ |
| 2005-01-25 | CHERELSTEIN STANLEY JACK | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2004-11-05 | Lonky Stewart Alan | Director | — | D | Common Stock | 0 | 0.00 | — | 500,000 | — | ↗ |
| 2004-11-05 | FLAX MICHAEL | Director | A-Award | A | Common Stock | 500,000 | 0.34 | 170.0K | 3,411,700 | — | ↗ |
| 2004-11-05 | DEITSCH RIK J | Director / Officer | A-Award | A | Common Stock | 500,000 | 0.34 | 170.0K | 1,500,000 | — | ↗ |
| 2004-11-05 | CHERELSTEIN STANLEY JACK | Director | — | D | Common Stock | 0 | 0.00 | — | 500,000 | — | ↗ |
| 2004-01-27 | FLAX MICHAEL | Director | J-Other | A | Common Stock | 598,000 | 200,000.00 | 119.60B | 3,205,200 | — | ↗ |
| 2003-12-31 | MCCLELLAND DAVID C SR | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2003-12-31 | KHALSA SORAM SINGH MD | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2003-12-31 | FLAX MICHAEL | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2003-12-31 | FELDER MITCHELL S | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2003-12-31 | ENGELBRECHT ZIRK | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2003-12-31 | DEITSCH RIK J | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2003-11-30 | FLAX MICHAEL | Director / Officer | S-Sale | D | Common Stock | 400,000 | 200,000.00 | 80.00B | 2,607,200 | — | ↗ |
| 2003-11-30 | ENGELBRECHT ZIRK | Director / Officer | S-Sale | A | Common Stock | 276,000 | 119,400.00 | 32.95B | 0 | — | ↗ |
| 2003-11-17 | MCCLELLAND DAVID C SR | Director | — | D | Nutra Pharma common stock | 0 | 0.00 | — | 505,000 | — | ↗ |
| 2003-10-30 | FELDER MITCHELL S | Director | — | D | Nutra Pharma Corp. common stock | 0 | 0.00 | — | 2,484,852 | — | ↗ |
| 2003-06-09 | DEITSCH RIK J | Officer | — | D | Nutra Pharma Corp. common stock | 0 | 0.00 | — | 1,000,000 | — | ↗ |
| 2002-12-31 | KHALSA SORAM SINGH MD | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2002-12-31 | ENGELBRECHT ZIRK | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-3.7K
Shares Outstanding
7.16B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dale VanderPutten | Chief Scientific Officer | 144.0K | — |
| Michael D. Flax | Chairman, Chief Executive Officer, President & Chief Financial Officer | 144.0K | — |
| Joe Lucas | Vice President of Operations | — | — |
| Nina Goldstein | Secretary | — | female |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NPHC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
